mhurhangee/ep-ind-claims huggingface dataset:
Method for influencing noise, wherein a noise source, in particular an engine in a motor vehicle, generates the noise by means of an essentially periodically changeable excitation, and wherein a reference variable that is characteristic of the noise source, in particular an engine rotational speed, is present at predetermined successive supply instants (t i), said method having the following steps: - reading out at least one first value (N i-1) of the reference variable at a first supply instant (t i-1) and a second predetermined value at a second supply instant (t i), characterised by means of - generating the reference signal at at least one instant (t) between the second supply instant (t i) and a third supply instant (t i+1) in dependence upon the first and second values that are read out, and - supplying the reference signal to a device for actively influencing noise and said device generates control signals for at least one actuator in dependence upon the reference signal, wherein the at least one actuator emits a compensating sound that interferes with the noise. - reading out at least one first value (N i-1) of the reference variable at a first supply instant (t i-1) and a second predetermined value at a second supply instant (t i), - generating the reference signal at at least one instant (t) between the second supply instant (t i) and a third supply instant (t i+1) in dependence upon the first and second values that are read out, and - supplying the reference signal to a device for actively influencing noise and said device generates control signals for at least one actuator in dependence upon the reference signal, wherein the at least one actuator emits a compensating sound that interferes with the noise.
A method for predicting recurrence of Hodgkin lymphoma in a subject treated with a first treatment regimen comprising: (a) providing an isolated sample from the subject and an isolated sample from a good clinical outcome control subject; (b) isolating total RNA comprising CD30 RNA, Fibroblast Growth Factor-2 RNA, TGFβ1 RNA, MMP9 RNA, and Syndecan-1 RNA from the isolated sample from the subject and from the isolated sample from the good clinical outcome control subject; (c) amplifying the total RNA from step (b); (d) measuring a level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in the isolated sample from the subject and in the isolated sample from the good clinical outcome control subject; (e) comparing the level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in step (d) in the isolated sample from the subject with the level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in step (d) in the isolated sample from the good clinical outcome control subject, wherein an increased level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in the isolated sample from the subject compared to the level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in the isolated sample from the good clinical outcome control subject is indicative of recurrence of HL in the subject; (f) predicting recurrence of Hodgkin lymphoma in the subject based on step (e). (a) providing an isolated sample from the subject and an isolated sample from a good clinical outcome control subject; (b) isolating total RNA comprising CD30 RNA, Fibroblast Growth Factor-2 RNA, TGFβ1 RNA, MMP9 RNA, and Syndecan-1 RNA from the isolated sample from the subject and from the isolated sample from the good clinical outcome control subject; (c) amplifying the total RNA from step (b); (d) measuring a level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in the isolated sample from the subject and in the isolated sample from the good clinical outcome control subject; (e) comparing the level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in step (d) in the isolated sample from the subject with the level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in step (d) in the isolated sample from the good clinical outcome control subject, wherein an increased level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in the isolated sample from the subject compared to the level of expression of the CD30 RNA, the FGF2 RNA, the TGFβ1 RNA, the MMP9 RNA, and the SDC1 RNA in the isolated sample from the good clinical outcome control subject is indicative of recurrence of HL in the subject; (f) predicting recurrence of Hodgkin lymphoma in the subject based on step (e).
Dispenser for a wound-up, web-shaped flat product comprising a housing part, a cover part and a conveyor unit, wherein the conveyor unit comprises at least one drum, wherein a loading device is assigned to the drum, wherein the loading device comprises a loading arm, wherein at least one roll with the web-shaped flat product can be inserted into the dispenser, wherein the web-shaped flat product can be arranged between the loading arm and the drum, wherein by means of the loading arm at least in an active position, the web-shaped flat product can be pressed against the drum, characterized in that the loading arm can be guided into in the active position by means of at least one spring which is attached at least to the cover part.
A topical ophthalmic sustained release composition for use in the transdermal delivery across the eyelid or systemic delivery of at least one therapeutic agent for treating an ophthalmic condition, said composition comprising a therapeutically effective amount of said at least one therapeutic agent suitable for treating the ophthalmic condition, and from about 0.001 to 50 wt% of a muscle fasciculating agent, selected from the group consisting of caffeine, theophylline, pentoxifyline and theobromide, wherein the composition is applied to the outer surface of one or both upper and/or lower eyelids of a human patient, and wherein the ophthalmic condition is selected from the group consisting of blepharitis, trachomatous dry eye, retinopathy, retinal degeneration, epiphora, allergic conjunctivitis and keratitis, infectious conjunctivitis and keratitis, pterygium, pinguiculum, iritis, uveitis, keratitis, vitritis, vitreous floaters, vitreous detachment, vitreous hemorrhage, retinal detachment, sub retinal hemorrhage, choridal neovascular membrane, retinal edema, macular edema, diabetic retinopathy, choridal malignancy, orbital malignancy, optic neuritis, optic neuropathy, strabismus, refractive error and glaucoma.
A user terminal comprising: a camera for capturing a video image at the user terminal; an input for receiving a video signal from a remote terminal via a communication network; a display for displaying to a user at the user terminal the captured video image and a video image derived from the received video signal, the video images (2a, 2b) each comprising a moving image; a selection input for receiving from the user at the user terminal at least one effect for enhancing the video image derived from the received video signal; a rendering device for rendering on the display the video image derived from the received video signal enhanced by the selected effect received by the selection input; and an input for receiving an indication of an effect selected at the remote terminal, wherein the rendering device is configured to render the same effect selected at the remote terminal to the captured video image displayed on the display. a camera for capturing a video image at the user terminal; an input for receiving a video signal from a remote terminal via a communication network; a display for displaying to a user at the user terminal the captured video image and a video image derived from the received video signal, the video images (2a, 2b) each comprising a moving image; a selection input for receiving from the user at the user terminal at least one effect for enhancing the video image derived from the received video signal; a rendering device for rendering on the display the video image derived from the received video signal enhanced by the selected effect received by the selection input; and an input for receiving an indication of an effect selected at the remote terminal, wherein the rendering device is configured to render the same effect selected at the remote terminal to the captured video image displayed on the display.
A wireless communication system comprising a first wireless communication device and a second communication device, and configured to transmit a feedback signal containing at least a forward link channel estimate value (h) from the first wireless communication device to the second wireless communication device, the first wireless communication device configured to transmit the feedback signal through a backward link (h'), comprising: a receiving unit configured to receive a signal containing pilot signals received from the second communication device; a channel estimation unit configured to determine the forward link channel estimate value, based on the signals received by the receiving unit; a multiplier configured to multiply a second pilot signal (S 2) by the forward link channel estimate value; a multiplexer configured to multiplex an output signal from the multiplier with a first pilot signal (S 1), to generate the feedback signal; and a transmitting unit configured to transmit the feedback signal; and the second wireless communication device comprising: a receiving unit configured to receive the feedback signal through a backward link (h'); a separator configured to separate the signals multiplexed in the feedback signal to obtain a first reception signal rf 1 and a second reception signal rf 2, the first and second reception signals affected by the backward link h' and expressed as: rf 1 = hʹs 1, and rf 2 = hʹhs 2; where s 1 is the first pilot signal and s 2 is the second pilot signal; and a channel estimation unit (524, 526) configured to determine the forward link channel estimate value (h), based on the separated signals and the first and second pilot signals. a receiving unit configured to receive a signal containing pilot signals received from the second communication device; a channel estimation unit configured to determine the forward link channel estimate value, based on the signals received by the receiving unit; a multiplier configured to multiply a second pilot signal (S 2) by the forward link channel estimate value; a multiplexer configured to multiplex an output signal from the multiplier with a first pilot signal (S 1), to generate the feedback signal; and a transmitting unit configured to transmit the feedback signal; a receiving unit configured to receive the feedback signal through a backward link (h'); a separator configured to separate the signals multiplexed in the feedback signal to obtain a first reception signal rf 1 and a second reception signal rf 2, the first and second reception signals affected by the backward link h' and expressed as: rf 1 = hʹs 1, and rf 2 = hʹhs 2; where s 1 is the first pilot signal and s 2 is the second pilot signal; and a channel estimation unit (524, 526) configured to determine the forward link channel estimate value (h), based on the separated signals and the first and second pilot signals.
A method of making an epoxy resin by a condensation of at least one polyphenolic compound and at least one condensation compound selected from epichlorohydrin, 1,3-dichloro-2-propanol, and homologs thereof in water that is free of added organic solvent at an elevated temperature of at least 30°C and in the presence of a catalyst, wherein the method comprises carrying out the condensation in the presence of at least one dispersion promoting agent which is a cellulose ether comprising a C 1-4 alkyl and/or C 1-4 hydroxyalkyl group whose solubility in water decreases with increasing temperature.
A method for diagnosing a likelihood of systemic lupus erythematosus in a subject at risk thereof, comprising (a) determining that a subject at risk of SLE is negative for SLE based on individual levels of the EC4d marker, the BC4d marker, anti-Smith (anti-Sm) antibodies, and double stranded DNA antibodies (anti-dsDNA); and (b) calculating an SLE risk score based on a level of each of the following primary markers in a biological sample from the subject at risk of SLE of step (a): an erythrocyte C4d (EC4d) marker; a B-cell C4d (BC4d) marker; and anti-nuclear antibodies; wherein the risk score indicated a likelihood of the subject having SLE. (a) determining that a subject at risk of SLE is negative for SLE based on individual levels of the EC4d marker, the BC4d marker, anti-Smith (anti-Sm) antibodies, and double stranded DNA antibodies (anti-dsDNA); and (b) calculating an SLE risk score based on a level of each of the following primary markers in a biological sample from the subject at risk of SLE of step (a): an erythrocyte C4d (EC4d) marker; a B-cell C4d (BC4d) marker; and anti-nuclear antibodies; an erythrocyte C4d (EC4d) marker; a B-cell C4d (BC4d) marker; and anti-nuclear antibodies;
A dual type drying machine comprising: a main drying unit comprising an opening/closing door provided at a front side thereof; an auxiliary drying unit disposed above the main drying unit and comprising an opening/closing door provided at a top surface of a laundry accommodation space; a stand provided inside the auxiliary drying unit; a cabinet surrounding an exterior of the main drying unit and an exterior of the auxiliary drying unit; and an operation panel disposed at the cabinet for operating the main drying unit and the auxiliary drying unit, wherein the opening/closing door of the auxiliary drying unit forms an exterior of a top surface of the auxiliary drying unit together with a top surface of the cabinet in a state in which the opening/closing door of the auxiliary drying unit is in a closed state, and wherein a rear side of the auxiliary drying unit protrudes backwards further than a rear side of the main drying unit. a main drying unit comprising an opening/closing door provided at a front side thereof; an auxiliary drying unit disposed above the main drying unit and comprising an opening/closing door provided at a top surface of a laundry accommodation space; a stand provided inside the auxiliary drying unit; a cabinet surrounding an exterior of the main drying unit and an exterior of the auxiliary drying unit; and an operation panel disposed at the cabinet for operating the main drying unit and the auxiliary drying unit, wherein the opening/closing door of the auxiliary drying unit forms an exterior of a top surface of the auxiliary drying unit together with a top surface of the cabinet in a state in which the opening/closing door of the auxiliary drying unit is in a closed state, and wherein a rear side of the auxiliary drying unit protrudes backwards further than a rear side of the main drying unit.
A process for preparing a peroxide-modified polyethylene comprising the steps of: preparing a first Ziegler-Natta-catalyzed polyethylene in a first reactor; transferring the first Ziegler-Natta-catalyzed polyethylene from the first reactor to a second reactor; admixing a first amount of an organic peroxide to the second reactor; reacting the organic peroxide with a polyethylene composition made from or containing the first Ziegler-Natta-catalyzed polyethylene, thereby coupling the polyethylene components and forming the peroxide-modified polyethylene; and collecting the peroxide-modified polyethylene. wherein the process further comprises the steps of: preparing a high density polyethylene in a third reactor; and transferring the high density polyethylene from the third reactor to the second reactor, And wherein the polyethylene composition further comprises the high density polyethylene. preparing a first Ziegler-Natta-catalyzed polyethylene in a first reactor; transferring the first Ziegler-Natta-catalyzed polyethylene from the first reactor to a second reactor; admixing a first amount of an organic peroxide to the second reactor; reacting the organic peroxide with a polyethylene composition made from or containing the first Ziegler-Natta-catalyzed polyethylene, thereby coupling the polyethylene components and forming the peroxide-modified polyethylene; and collecting the peroxide-modified polyethylene. preparing a high density polyethylene in a third reactor; and transferring the high density polyethylene from the third reactor to the second reactor, And wherein the polyethylene composition further comprises the high density polyethylene.
Formulation of metal, metal oxide or semi-conductor nanocrystals chosen from gold nanocrystals, silver nanocrystals, iron oxide nanocrystals, gadolinium oxide nanocrystals, hafnium oxide nanocrystals and luminescent or fluorescent semiconductor nanocrystals in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase encapsulating the nanocrystals, - wherein the oily phase comprises: - at least one phospholipid, and - at least one solubilising lipid consisting of a mixture of saturated fatty acids glycerides comprising: - at least 10% by weight C12 fatty acids, - at least 5% by weight C14 fatty acids, - at least 5% by weight C16 fatty acids and - at least 5% by weight C18 fatty acids, and - wherein the aqueous phase comprises a cosurfactant. - wherein the oily phase comprises: - at least one phospholipid, and - at least one solubilising lipid consisting of a mixture of saturated fatty acids glycerides comprising: - at least 10% by weight C12 fatty acids, - at least 5% by weight C14 fatty acids, - at least 5% by weight C16 fatty acids and - at least 5% by weight C18 fatty acids, and - at least one phospholipid, and - at least one solubilising lipid consisting of a mixture of saturated fatty acids glycerides comprising: - at least 10% by weight C12 fatty acids, - at least 5% by weight C14 fatty acids, - at least 5% by weight C16 fatty acids and - at least 5% by weight C18 fatty acids, and - at least 10% by weight C12 fatty acids, - at least 5% by weight C14 fatty acids, - at least 5% by weight C16 fatty acids and - at least 5% by weight C18 fatty acids, and - wherein the aqueous phase comprises a cosurfactant.
Receiver for solar concentrating systems comprising: - a container including at least one transparent wall configured to receive solar rays from a solar concentrator and defining at least one cavity of housing, - a conversion module configured to convert solar energy taken from said solar rays into thermal and/or electrical energy and housed within a part of said cavity close to said wall and separated from said wall by a slot, - transparent optical gel housed within said cavity and configured to completely occupy at least said slot so as to shield said conversion module, and characterized in that said container comprises one or more bearings housed within said cavity and configured to expand in proportion to said gel in such a way that compensates eventual dilations of said gel. - a container including at least one transparent wall configured to receive solar rays from a solar concentrator and defining at least one cavity of housing, - a conversion module configured to convert solar energy taken from said solar rays into thermal and/or electrical energy and housed within a part of said cavity close to said wall and separated from said wall by a slot, - transparent optical gel housed within said cavity and configured to completely occupy at least said slot so as to shield said conversion module, and characterized in that
A pharmaceutical composition for use in the treatment or prevention of a cancer in an HLA-A*1101-positive subject, comprising a peptide consisting of an amino acid sequence or: an amino acid sequence of Pro Ile Leu Cys Gly Ala Gin Tyr Arg (SEQ ID NO: 3), an amino acid sequence of SEQ ID NO:3, in which one amino acid is substituted with another amino acid, wherein the peptide consisting of the amino acid sequence of has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL. an amino acid sequence of Pro Ile Leu Cys Gly Ala Gin Tyr Arg (SEQ ID NO: 3), an amino acid sequence of SEQ ID NO:3, in which one amino acid is substituted with another amino acid, wherein the peptide consisting of the amino acid sequence of has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL.
A method of assigning a physical resource block to one of a plurality of user equipments (UEs), the method comprising: measuring interference on the PRB at a serving cell, the serving cell configured to serve the plurality of UEs; receiving measurements of interference on the PRB from neighbor cells of the serving cell; estimating a contribution from each UE of the plurality of UEs to each of the neighbor-cell interference measurements; determining, for each UE of the plurality of UEs, a respective enhanced priority ratio as a function of the interference measurement at the serving cell, the interference measurements received from the neighbor cells and the respective estimated contribution of the UE; and assigning the PRB to one of the plurality of UEs based on the determined enhanced priority ratios. measuring interference on the PRB at a serving cell, the serving cell configured to serve the plurality of UEs; receiving measurements of interference on the PRB from neighbor cells of the serving cell; estimating a contribution from each UE of the plurality of UEs to each of the neighbor-cell interference measurements; determining, for each UE of the plurality of UEs, a respective enhanced priority ratio as a function of the interference measurement at the serving cell, the interference measurements received from the neighbor cells and the respective estimated contribution of the UE; and assigning the PRB to one of the plurality of UEs based on the determined enhanced priority ratios.
A composition for use in treating a bleeding disorder comprising prothrombin and activated factor X (FXa) wherein the molar ratio of FXa to FII is more than 1:20,000.